Difference between revisions of "Team:Queens Canada/Lab"

Line 21: Line 21:
  
 
<p style="width:70%;margin-left:15%">
 
<p style="width:70%;margin-left:15%">
−
To develop a biosensor, we took two design approaches (link to design here!!!!!!!!!!!!!). At the core of both approaches is a modular Nuclear Receptor Ligand binding domain for binding to an analyte. Immediately flanking the ligand binding domain was two linkers of 3-11 amino acids in length, the selection of appropriate linkers was aided by extensive in-silico modelling, and root-mean-square deviation molecular dynamic modelling. On the ends of each linker was our signal transduction system which acts as our method of producing a signal once a ligand has bound the receptor.
+
To develop a biosensor, we took two <a href="https://2018.igem.org/Team:Queens_Canada/Design">design approaches.</a> At the core of both approaches is a modular Nuclear Receptor Ligand binding domain for binding to an analyte. Immediately flanking the ligand binding domain was two linkers of 3-11 amino acids in length, the selection of appropriate linkers was aided by extensive in-silico modelling, and root-mean-square deviation molecular dynamic modelling. On the ends of each linker was our signal transduction system which acts as our method of producing a signal once a ligand has bound the receptor.
 
<p>
 
<p>
 
<img style="width:70%;margin-left:15%" src="https://static.igem.org/mediawiki/2018/2/28/T--Queens_Canada--intein2D.png"/>
 
<img style="width:70%;margin-left:15%" src="https://static.igem.org/mediawiki/2018/2/28/T--Queens_Canada--intein2D.png"/>

Revision as of 01:26, 13 October 2018

Laboratory

To develop a biosensor, we took two design approaches. At the core of both approaches is a modular Nuclear Receptor Ligand binding domain for binding to an analyte. Immediately flanking the ligand binding domain was two linkers of 3-11 amino acids in length, the selection of appropriate linkers was aided by extensive in-silico modelling, and root-mean-square deviation molecular dynamic modelling. On the ends of each linker was our signal transduction system which acts as our method of producing a signal once a ligand has bound the receptor.

For the intein based approach the final signal transduction system was a Nano lucfierase which its split halves would be joined through splicing together two halves of the RecA split intein. To start however, we first sought to validate our intein splicing in bacterial system as selected through kanamycin resitance, and the utility of NanoLuc luciferase as a strong light source. Upon favorable results with NanoLuc, a portable luminometer was constructed and further tested (see hardware).

For the FRET based approach this system consisted of attaching a Fluorescent Protein with a low peak emission to our N-Terminal linker, our FRET donor, and a Fluorescent Protein with a red shifted emission to the C-terminal, our FRET acceptor. FRET function was validated firstly with a fluorometer, and then quantified with Confocal microscopy.